Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. (2021)
Attributed to:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bcp.14619
PubMed Identifier: 33085781
Publication URI: http://europepmc.org/abstract/MED/33085781
Type: Journal Article/Review
Volume: 87
Parent Publication: British journal of clinical pharmacology
Issue: 4
ISSN: 0306-5251